In this study, we used single nucleotide polymorphism and comparative genomic hybridization array to study DNA copy number changes and loss of heterozygosity for 28 patients affected by Sézary syndrome (SS), a rare form of cutaneous Tcell lymphoma (CTCL). Our data identified, further confirming previous studies, recurrent losses of 17p13.2-p11.2 and 10p12.1-q26.3 occurring in 71% and 68% of cases, respectively; common gains were detected for 17p11.2-q25.3 (64%) and chromosome 8/8q (50%). Moreover, we identified novel genomic lesions recurring in >30% of tumors: loss of 9q13-q21.33 and gain of 10p15.3-10p12.2. Individual chromosomal aberrations did not show a significant correlation with prognosis; however, when more than three recurrent chromosomal alterations (gain or loss) were considered, a statistical association was observed using Kaplan-Meier survival analysis. Integrating mapping and transcriptional data, we were able to identify a total of 113 deregulated transcripts in aberrant chromosomal regions that included cancer-related genes such as members of the NF-κB pathway (BAG4, BTRC, NKIRAS2, PSMD3, and TRAF2) that might explain its constitutive activation in CTCL. Matching this list of genes with those discriminating patients with different survival times, we identify several common candidates that might exert critical roles in SS, such as BUB3 and PIP5K1B. Altogether, our study confirms and maps more precisely the regions of gain and loss and, combined to transcriptional profiles, suggests a novel set of genes of potential interest in SS. [Cancer Res 2009;69(21):8438-46] 
Introduction
Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL) that typically presents with erythroderma, peripheral lymphadenopathy, severe pruritus, and malignant circulating CD4 + T lymphocytes: the Sézary cells (1) .
Conventional cytogenetics, allelotyping, and comparative genomic hybridization (CGH) analyses have shown that these tumor cells exhibit chromosomal instability, manifested as allelic gain, loss, or rearrangement (2) . Although numerous efforts have been made to clarify how the genomic aberrations might predispose to the development of this disease, the identification of pathogenically relevant genes still remains a challenge. Recently, the application of high-throughput technologies for genome-wide surveys of genetic or expression profiles in CTCL are giving new insights into this malignancy (3) (4) (5) (6) . Furthermore, there is an increasing tendency to integrate mapping and expression data to study the relationship between copy number changes and gene expression levels as a significant fraction of genes are altered in a manner consistent with the underlying genomic alterations in a variety of tumors (7) (8) (9) (10) (11) including CTCL (12, 13) . The presence of recurrent chromosomal copy number alterations (CNA) that correlate with disease outcome suggests that changes in the expression of specific genes within these regions are critical to the disease process (14) .
Here, we describe a genome-wide analysis, at submegabase resolution, of DNA copy number changes in 28 SS samples using the single nucleotide polymorphism (SNP) and array CGH (aCGH) technology. Our findings identified six regions of highly recurrent copy number aberrations affecting chromosomes 8, 9, 10, and 17. Additionally, the SNP technology allowed us to distinguish between loss of heterozygosity (LOH) associated with either copy number changes, such as hemizygous deletions, or copy number neutral status, underlying the involvement of different genetic mechanisms that lead to uniparental disomy (UPD) in SS (15) . In the attempt to correlate copy number data and clinical parameters, we find a relationship between complex pattern of chromosomal aberrations, involving at least three recurrent CNAs, and shorter survival. We then combined copy number results with gene expression data from the same SS patients to generate a signature of genes differentially expressed and located within the chromosomal regions of interest that include novel potential candidates of SS tumor development.
Materials and Methods
Patients. Peripheral blood samples from 28 SS-affected individuals were analyzed. All the patients were enrolled in clinical protocols approved by the Ethical Committee of the Istituto Dermopatico dell'Immacolata, and informed consent was obtained in accordance with the Declaration of Helsinki. Diagnosis of SS was based on described criteria (16) . The major clinical and immunologic characteristics, including T-cell receptor clonal analysis (17) of the samples, are listed in Supplementary Table S1 .
Tumor, normal cell isolation, and genomic DNA extraction. Peripheral blood mononuclear cells were separated by Ficoll-Histopaque density gradient centrifugation (Sigma-Aldrich). Lymphomonocytes and granulocytes were separately collected from the gradient fractions. Lymphomonocytes were subsequently purified by positive selection using anti-human CD3-conjugated dynabeads (Oxoid Ltd.). Granulocytes (normal matched cells) were obtained collecting the upper phase overlaying the Ficoll density gradient sediment; residual erythrocytes were then lysed by repetitive washes with a solution of 10 mmol/L Tris-HCl (pH 7.6), 5 mmol/L MgCl 2 , and 10 mmol/L NaCl. Tumor genomic DNA was isolated from sorted CD3 + / CD4 + T lymphocytes of SS patients, whereas normal matched DNA was extracted from the granulocytes of the same individuals according to published protocols (17) . The calculated percentage of tumor cells after purification is indicated for each sample in Supplementary Table S1 and  ranged from 35% to 91%. SNP genotyping, LOH, and DNA copy number change. The samples were analyzed on the GeneChip Human Mapping 10K Array Xba 142 (Affymetrix) containing ∼10,000 tiled SNPs (median intermarker distance, 105 Kb). DNA was prepared for hybridization using the GeneChip Human Mapping 10K Xba Assay kit (Affymetrix). Genotype calls and signal information were obtained using GCOS 1.4 and GTYPE 4.0 software (Affymetrix). SNP arrays were then analyzed using dChipSNP software, 4 allowing the simultaneous measurement of LOH and DNA copy number changes (18) . To compute LOH, in a pair of normal and tumor DNA, dChipSNP assigned the following calls: L, Loss (AB in normal A or B in tumor); R, retention (AB both in normal and tumor); and N, noninformative or no call (homozygous A or B in normal and tumor; AB, A, B, and no call in normal or tumor); the LOH status, inferred from the observed L calls, used Hidden Markov Model. For copy number determination (15) after normalization to a baseline array using the invariant set normalization method, a modelbased method (PM/MM) was used to compute the signal values for each SNP in each array. To infer the DNA copy number from the raw signal data, the Hidden Markov Model was used applying subinteger inferred step of 0.2. Genomic gains and losses were defined as inferred copy number of >2.4 and <1.8, respectively; these threshold values of dChipSNP-copy number determination were chosen as they correspond to copy number measures made by aCGH.
Mapping information of SNP loci and cytogenetic band are derived from Affymetrix and University of California Santa Cruz 5 (hg 17 human genome assembly).
aCGH. aCGH analysis was performed using the Human Genome CGH Microarray kit 44B (Agilent Technologies) comprising 60-mer oligonucleotides spaced ∼75 kb density over the full genome. Digestions, labeling, and hybridization were performed following the Agilent manufacturer's protocols (version 5.0). Images were analyzed using Agilent Feature Extraction Software version 9.5.1 and data were imported into Agilent CGH analytics software version 3.5 for a graphical overview and analysis. Analysis was performed using the ADM-2 algorithm (Agilent Technologies) with a threshold of 5.3. Experiments showing a derivative log ratio spread value of >0.3 were excluded from the analysis.
RNA isolation, labeling, and gene expression analysis. Five micrograms of total RNA extracted from sorted T lymphocytes, according to Affymetrix procedure, were reverse transcribed, synthesized in cRNA, fragmented, labeled, and hybridized to Human Genome U133A arrays. The scanned data were analyzed with a customized script that uses Bioconductor packages 6 based on the R language, 7 for quality control assessment, data normalization, unsupervised and supervised clustering analysis, and identification of differentially expressed transcripts (19) . This R-script provides utilization of different Bioconductor packages; gcrma package was used for normalization and background correction, and Genefilter package was used to filter genes with highly variance by interquartile range method; samr-package, significance analysis of microarrays (20) was used for detecting significantly expressed genes and controlling the false discovery rate between groups of tumor samples.
Survival and statistical analyses. A time-to-event analysis was performed using nonparametric Kaplan-Meier product-limit survival estimates, and differences between Kaplan-Meier survival curves were analyzed using the Mantel-Haenszel log-rank test. Statistical analyses were performed using Statistical Package SPSS v. 13.0.
Quantitative real-time PCR. Quantitative RT-PCR was performed using a SensiMix DNA kit (Quantace Ltd) on a ABI PRISM 7000 Sequence Detection System (Applied Biosystem). Primers, designed by using Primer3 Input 0.4.0, were synthesized by Eurofins MWG Operon. Quantification of tumor DNA alterations was performed by comparing the target locus to the reference Line-1 (21) , and copy number changes of target genes were determined as described (15) . Primers for each target are shown in Supplementary Table S2 . We have used reverse quantitative RT-PCR to validate gene expression data as previously described (16) using, for each gene, a reference RNA pool chosen from those tumors with no CNA; primers' sequences are indicated in Supplementary Fig. S1 .
Results
CNAs: detection of copy number loss and gain. Tumor and paired normal samples from 28 SS patients were genotyped using 10K SNP arrays. The abnormalities found by SNP chip analyses in 24 of these patients were verified by comparison to those detected by aCGH studies. The copy number regions were determined according to the hybridization intensity data generated from each genotype probe on the mapping array comparing normal and tumor samples. The result of the genome-wide analysis of CNAs, showing the most frequent regions involved in gain or loss of genetic material is represented, as summary plot, in Supplementary  Fig. S2 . The computed copy number summary score identified three regions of copy number loss and three regions of gain as highly recurrent (>30%). The relative sizes and boundaries were then mapped referring to the SNP analysis (Table 1) . Copy number loss. The most common allelic loss, occurring in 71% of tumors, was on the short arm of chromosome 17. Nineteen cases showed broad regions of deletion largely overlapping within 17p13.2-p11.2 and one sample (P49) exhibited whole chromosome 17 loss (Table 2) . Loss of genetic material spanning 10p12.1-q26.3 was found in 68% of cases. As outlined in Fig. 1 and detailed in Table 2 , seven tumors (P2, P22, P32, P36, P42, P48, and P49) displayed one single deletion involving the long arm and the pericentromeric region that, in one case (P49), was extended to the short arm. Six additional cases (P5, P8, P15, P25, P34, and P39) exhibit the cooccurrence of two discrete areas of loss, one within 10p12.1-q21.3 and the second in 10q23.1-q26.3. Three samples showed regions of deletion encompassing only 10p12.1-q11.21 (P23, P27, and P45) and three further cases solely 10q23.2-q26.3 (P7, P28, and P35). We also found a highly recurrent region of loss within 9q13-q21. 33 , present in 9 of 28 samples (32%), which was not previously reported among the common deletions in CTCL (Table 1 ; Fig. 1 ).
Genome-wide analysis of copy number losses enable also the detection of homozygous deletions (HD) that are of particular interest as they may unveil the presence of tumor suppressor genes. Two HDs were unequivocally identified in patient P28: the first one, encompassing 34 consecutive SNP loci with inferred copy number of 0.2 over 6.4 Mb, occurred on 9p21.3-p21.2 locus and included tumor suppressor genes CDKN2A and CDKN2B (Fig. 2) ; the second HD (∼2 Mb segment with three consecutive SNPs of inferred copy number values of 0.2) was identified on chromosome 13q14.2 encompassing the RB1 locus (data not shown). Both these HDs have been confirmed by quantitative RT-PCR experiments performed on tumor DNA from patient P28 (Supplementary  Table S2 ). Furthermore, a potential HD, defined as inferred copy number of 0.6 in 21 consecutive markers, has been identified in patient P48; the flanking SNPs describe a 3.97-Mb area at 9p21.3 that, similar to P28 case, includes the CDKN2A and CDKN2B. Finally, all the samples exhibited the loss of the T-cell receptor α and δ chains locus due to the physiologic recombination of V and J gene segments, confirming, therefore, the homogenous selection of T lymphocytes in our tumor samples (data not shown).
Copy number gain. The most frequent region of copy number gain, present in 64% of samples, was on the long arm of chromosome 17 (17p11.2-q25.3). We observed that 16 of 18 patients exhibit the gain of 17q region associated with the concurrent deletion of 17p (Table 2 ). This suggests the presence of an isochromosome 17q (iso17q), a chromosomal abnormality that shows a relatively high frequency in our group of SS patients (57%). High-resolution mapping of the breakpoints associated with loss of 17p and gain of 17q revealed scattering of the breakpoints over 7.2 Mb in 17p12-q11.1 (15.2-22.4 Mb). Another recurrent gain involved chromosome 8 in 14 of 28 (50%) cases; the whole chromosome 8 (8p23.3-q24.3) resulted affected by copy number gain in eight tumor samples (P2, P7, P22, P27, P35, P42, P50, and P51), whereas the remaining six cases showed a gain of chromosomal regions varying between 53.12 and 107.84 Mb mainly involving the long arm (Table 2 ; Fig. 1 ).
Lastly, we identified chromosome 10p15.3-p12.2 commonly affected by copy number gain as 10 of 28 samples (36%) display this chromosomal abnormality. It may be considered a novel recurrent genetic lesion in CTCL because it has not been described yet. The extension of copy number gain of chromosome 10p in our sample group ranged from 2.76 Mb (P23), within 10p15.1-p14, to a 26-Mb region (P42) spanning 10p15.3-p12.1 (Table 2 ; Fig. 1 ). In our data set, chromosome 10 was affected by complex allelic imbalances so that tumors with gain of 10p showed concomitant loss of short arm regions in two cases (P23, P45); similarly, 10q24.32-q26.3 deletion cooccurred with 10p gain in patients P28 and P35. In six cases (P2, P25, P36, P39, P42, and P48), all the above-mentioned allelic imbalances were simultaneously present.
Analysis of LOH and DNA copy number change. The SNP mapping array enabled us to assess the concurrent status of LOH and CNAs. We included in the LOH analysis tumor samples displaying consistent regions of deletion defined as more than three contiguous deleted SNPs (22) . We found a good correlation between LOH and copy number data for all the above-described recurrent deletions affecting chromosomes 9, 10, and 17 ( Fig. 2) . However, we observed that some individuals, displaying LOH, do not exhibit copy number changes, a condition that might be explained with copy-neutral LOH events also known as UPD (23) . The highest incidence, with six samples displaying UPD events, was detected for chromosome 10, whereas not more than two cases have been detected for other chromosomes such as 17 and 9 (boxed areas in Fig. 2 ). These regions generally span interstitial areas of LOH or telomeric ends and they usually interest relatively small areas (∼10-60 SNP markers), with the exception of UPDs exhibited by patient P28 for 10p12.1-q24.3 (303 SNPs over 78 Mb; Fig. 2 ) and 13q12.11-q14.2 (143 SNPs in ∼29 Mb; data not shown). Besides UPD, we found one case (P23) showing a chromosomal area of ∼7.3 Mb (24 SNPs) on 10p12.31-p12.1 with inferred copy number value of >5. This patient, however, exhibits concomitant LOH of this region (Fig. 2) , suggesting that the LOH might be due to the amplification, rather than loss, of one of the allele. The use of SNP technique allowed for a more complete understanding of the complex genetic rearrangements underlying SS pathology.
Identification of genes differentially expressed in regions of genomic gain and loss. Because we had expression data for the majority of our samples (20 of 28 cases, indicated in bold in Table 2 ), we sought to determine the impact of CNAs on gene expression. To this end, we have dichotomized our data set for each of the highly recurrent chromosomal imbalances, grouping the samples on the basis of the presence or absence of each specific CNA (see Supplementary Table S3 and Info for details). As a result, we were able to identify a total of 113 genes (136 probe sets) differentially expressed in regions of genomic imbalances (twosample t test P < 0.01): (a) 53 genes within chromosome 17, 94% of which matched the CNAs of this chromosome; (b) 21 encompassing CNAs of chromosome 10, all of which correspondingly upregulated or downregulated; (c) 24 genes spanning chromosome 9, the 85% were concordantly underexpressed; (d) 15 overexpressed transcripts (100%) matched chromosome 8 gain. A complete list of these genes is reported in Supplementary Table S4 . The means of the observed fold change values of gene expression were 1.33 (log 2 ratio = 0.41) for copy number gains and 0.75 (log 2 ratio = −0.43) for copy number loss consistent with a dosage effect [2-fold change in DNA copy number corresponds to 1.4-to 1.5-fold change in mRNA level (24) ]. Real-time PCRs further confirmed some of these data ( Supplementary Fig. S1 ). The search for cancer-related genes, Table S4) . Analysis of CNAs, expression profile, and survival. We then asked if, as in other leukemias, a correlation existed between CNAs and clinical outcome. Taken singularly, or in several combinations, any CNAs showed a significant association with survival time in our data set (data not shown). However, when we divided the patients on the basis of a complex aberration pattern, defined as three or more recurrent CNAs, a decreased overall survival was observed for individuals with ≥3 alterations (P = 0.05; Fig. 3A) . No significant difference, using the Mann-Whitney test, was seen between the observation times (i.e., copy number analysis), relative to the disease onset, for patients with <3 (median, 93.2 months) and ≥3 CNAs (median, 66.5 months). Therefore, we used the available expression data to identify genes differentially expressed between tumors harboring more (14 patients) or less (6 patients) than three CNAs. A total of 352 gene probes were found statistically significant (two-sample t test P < 0.05); this list has been then used in a supervised hierarchical clustering of a larger data set that included five normal samples, two Mycosis fungoides (MF) patients (P40, P44) displaying a normal chromosomal profile (data not shown), and eight additional SS tumors (P01, P04, P16, P18, P19, P21, P26, and P46) for whom mapping data were not available. As illustrated in Fig. 3B , this set of 352 genes was able to clearly discriminate two sample groups where healthy individuals (R1-R5) and MF patients clustered with the tumor samples harboring less than three CNAs, whereas only one sample with known complex genomic aberrations (P36) was included in the same samples set. This suggests that genes with predictive value of a different SS clinical course might be comprised in the list. We then compared these differentially expressed genes to those located in aberrant regions of CNAs identifying 12 genes. They were distributed across the identified regions of recurrent aberration: chromosome 9 comprised three deregulated genes (PIP5K1B, FLJ10232, and SET), of which PIP5K1B mapped to the recurrent region of deletion on 9q13-q21.33; four probe sets (three genes) spanned the 10q22.3-q26.3 genomic interval of copy number loss (MGEA5, PDCD11, and BUB3); two genes, TIMM22 and ABR, map head-to-head within the common deleted 17p13 locus, whereas 17q gained region encompasses PSMD3 and PSMC5; finally, two genes were found on chromosome 8 (ADRA1A, DPYS). Although further investigations are required to correlate genomic alterations and the clinical course of SS, these genes might represent novel candidates involved in the pathogenesis of this neoplasm.
Discussion
Allelic imbalance is a common feature of many malignancies. We have measured allelic imbalance in a series of SS patients using SNP oligonucleotide microarrays and aCGH. Both these techniques enable genotyping with a comparable high-level resolution comprised between 75 and 105 Kb. The SNP analysis for copy number determination identified three common regions of loss within 9q13-q21.33, 10p12.1-q26.3 and 17p13.2-p11.2, whereas copy number gain were defined for 8p23.3-q24.3, 10p15.3-p12.2, and 17p11.2-q25.3. These chromosomes have long been established to be among the mostly affected by cytogenetic aberrations in CTCL using conventional techniques (2, (26) (27) (28) (29) (30) (31) . More recently, aCGH has been used by Vermeer and colleagues (3) in a genome-wide survey of 20 SS cases; their findings identified 17p13.1-p11.2 loss in 75% of cases, a complex pattern of deletions of chromosome 10 with eight discrete regions of highly recurrent loss (40-60%). Gains were observed for 17q21.31-q23 (80%) and 8q24.1-q24.3 (75%); several scattered minimal common gained areas across the long arm of chromosome 8 were also reported. Our results show a substantial agreement with these data; however, main differences were Cancer Research observed for chromosome 10 losses and for regions of gain. Although our data confirmed the complex profile of alterations affecting chromosome 10, we identified two prevalent lost regions of variable length within 10p12.1-q22.1 and 10q22.3-q26.3 that very often cooccur in tumor samples. Concerning 17q, we detected a wider region of recurrent gain extending from the pericentromeric (17p11.2-q11.1) to the subtelomeric area of the long arm (17q21.33-q24.3); furthermore, in our data set, we observed a prevalence of 17p loss (71%) with respect to 17q gain (64%), and a large fraction of our cases (57%) had imbalances compatible with the presence of iso17q. Regarding chromosome 8, we were not able to identify minimal common regions of gain; we observed a rather homogeneous alteration of the whole chromosome 8 or 8q involving about the 50% of our sample group. Finally, we were able to detect two additional regions of allelic imbalance: 10p15.3-p12.2 gain, further increasing the pattern of complexity observed for this chromosome, and 9q13-q21.33 loss; to our knowledge, these were not previously reported in SS and may, therefore, be considered novel recurrent genetic lesions. The slight discrepancies observed between the studies may reflect methodologic approaches using different resolutions; however, altogether, these studies identified the most common allelic imbalances in SS. Paired tumor/control samples allow the identification of LOH by true allelic imbalance (i.e., LOH associated with copy number loss) or acquired UPD, a mechanism responsible for LOH without a change in copy number. In cancer biology, it might unveil genes that are downregulated through epigenetic mechanisms or mutations, but still retain a diploid copy number (32) . Events of UPD might be due to: (a) mitotic nondisjunction, leading to UPD of a whole chromosome, (b) recombination between chromatids, resulting in UPD of a chromosomal arm or telomeric ends, (c) multiple recombination events, determining interstitial regions of UPD (9, 23) . In the SS cases analyzed, we could find several small and few large UPDs involving interstitial or telomeric regions of LOH occurring mainly for chromosome 10 and to a lesser extent for chromosome 9 and 17. This suggests that in SS cells, UPD might arise through mechanisms of mitotic recombination rather than nondisjunction events and that DNA double-strand breaks repair might be important in the etiology of this disease. This obviously requires the investigation of a larger number of individuals and the identification of mutations within key SS-specific genes contained within the runs of UPD. In addition to UPD, we were also able to detect LOH and simultaneous copy number gain of 10p12.31-p12.1 in one patient (P23) that is explained by the overrepresentation of one of the allele rather than true LOH. Noticeably, this is the only focal high-amplitude alteration that occurred in our data set of tumor samples, suggesting that high-level gene amplification events are not a feature of SS. Our results indicate that large regions of low-level copy number gains (inferred copy number between 2.4 and 3.4), likely corresponding to duplication events, are prevalent in this malignancy. Similarly, HDs were not frequently observed in our series of SS patients, and although all those identified matched well-known tumor suppressor genes (CDKN2A, CDKN2B, RB1) already described in CTCL (30, 33, 34) , they do not occur in the highly recurrent regions of copy number loss. This suggests that they might represent sporadic events further worsening the pattern of chromosomal aberrations of the tumor cell.
We have then used the fine-mapped regions of recurrent CNAs to perform a comparison of expression level between classes of tumors with a given CNA and tumors lacking that CNA. This approach of combining copy number and gene expression data has been successful in other indications (7, 9, 11, 35) ; the impact of copy number on gene expression pattern shows generally more dramatic effects in the case of high-level copy number increase, whereas low-level copy number gains and losses, although have significant influence on expression of genes in the regions affected, display more subtle effects on a gene-by-gene basis (24, 36) . Therefore, we applied stringent parameters of statistical significance to identify genes whose differential expression is more likely to be attributable to underlying low-level gene copy number changes; this led to the identification of 113 genes differentially expressed in regions of genomic gain and loss. Importantly, several of these genes have been already implicated in the molecular pathogenesis of CTCL such as MXI1 (3), HSF1, NFE2L1, SUPT4H1, DDX42, and ICAM2 (5, 13), providing, therefore, a measure of validation for the described study. Other genes have been previously reported in this lymphoma as important candidates for cancer development such as NME1 and RPA1 (3, 37) . For this latter gene, in vivo studies showed that, if mutated, it results in defective DNA double-strand break repair, chromosomal instability, and development of lymphoid tumors (38) . A key molecular feature of CTCL is the constitutive activation of NF-κB that is involved in survival and apoptosis of SS cells (39, 40) ; interestingly, in our list of deregulated genes, we found a total of 5 genes related to the TNFα/NF-κB pathway (BAG4 8p12, BTRC 10q24.32, NKIRAS2 17q21.2, PSMD3 17q12-q21.1, and TRAF2 9q34), thereby suggesting that the recurrent low-level copy number changes, and the concomitant imbalance in gene expression, might disrupt critical stochiometric relationships in SS cell, possibly promoting tumor development or progression. It should be also noted that these analyses may represent an underestimate of the mRNA variation levels directly attributed to variation in gene copy number as this is affected not only by true variation in the expression programs of the tumor cells themselves, but also by the variable presence of no-tumor cell types within clinical samples (24) . Therefore, a larger number of genes in SS could be deregulated as a consequence of copy number changes.
Previous studies in CTCL have shown the agreement between aberration rate and change of clinical conditions and outcome (28, 41) . Similar to Espinet and colleagues (27) , we have found that as few as three recurrent CNAs are sufficient to reduce the overall survival; however, aberrations in a number of individual chromosome did not result in a significant correlation with prognosis. This might be due to the sample size (28 patients) that prevents to run robust statistical analysis, but also to the requirement of alteration or biallelic inactivation (e.g., point mutation, epigenetic inactivation) of one or more specific critical genes. Comparing the expression profiles of SS cases harboring three or more CNAs with those exhibiting less than three genetic lesions, we have found a set of 352 genes that, when further tested in a larger data set of CTCL and healthy samples, seem to have a prognostic value. Interestingly, this list of transcripts comprised 12 deregulated genes located in the recurrent regions of imbalance. Among them, particularly important is BUB3 (10q26), as this gene is an essential component of the mitotic checkpoint pathway whose function ensures genomic stability (42) . Mutations in essential checkpoint proteins lead to chromosome instability and promote carcinogenesis (43) . Since . Each sample is depicted as a series of vertical bars in both the LOH and copy number panels. Blue areas, regions of LOH; yellow areas, retention of heterozygosity. The color intensities of inferred markers decline to the white as the distance from the nearest informative markers increases (18) . Copy number is marked by shades of red ranging from light red for copy of ≤1 to dark red for copies of ≥3 (see scale at the bottom of the panel); white color is for 0 copies corresponding to HD. Boxed regions, UPD events.
we and others have shown that SS genome harbors a high rate of chromosomal changes, BUB3 might play a critical role in the etiology of this neoplasm. Also important are cancer genes such as SET (9q34), ADRA1A (8p21-p11.2), and the members of the 26S proteasome enzyme complex PSMD3 (17q12-q21.1) and PSMC5 (17q23-q25). The first one is a well-known oncoprotein involved in chromatin modeling, transcription, cell cycle control, and protein phosphatase 2A inhibition (44) (45) (46) (47) . The second has been implicated in growth-promoting pathways (48) , whereas the ubiquitinproteasome pathway is required for the activation of NF-κB (40) . One transcript, PIP5K1B, maps to the novel recurrent region of deletion 9q13-q21. 33 ; it has been found to regulate directional leukocyte motility (49) . This activity, if deregulated, might result in the dysfunction of leukocyte responses, such as extravasation and antigen recognition, but also induction and/or inhibition of cellular programs that lead to activation, proliferation, and survival (50) . A detailed characterization of these genes may provide new biological insights into SS and might lead to the development of novel clinical tools.
Taken together, our data support the hypothesis that SS is a complex disease and occurs as a consequence of multiple genetic lesions: we found a correlation between complex profiles of aberration and overall survival in our series, as well as a novel signature of genes of potential pathogenetic interest within regions of loss/gain.
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